Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| GN2835 | Other Grant/Funding Number | Action Medical Research | |
| IRAS 297793 | Other Identifier | Health Research Authority |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Guy's and St Thomas' NHS Foundation Trust | OTHER |
| Action Medical Research | OTHER |
Not provided
Not provided
Not provided
Not provided
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody encephalitis), a rare condition which mainly affects children and young people and causes difficulties in memory, thinking and mental health which can have significant long-term impacts on education, employment and quality of life.
In this project we will use advanced magnetic resonance imaging (MRI) to measure changes in the structure, function and chemistry of the brains of children and young people who are in early recovery from NMDAR-antibody encephalitis and other forms of immune-mediated encephalitis. We will investigate if MRI measurements in patients differ from those in healthy people, and if they can help predict patient outcome one year later, assessed by tests of memory, thinking, mental health and functioning in daily life.
This study aims to develop non-invasive, in vivo measures of neurobiological dysfunction derived from the overarching hypothesis that dysfunction of inhibitory interneurons alters the cerebral concentrations of gamma-aminobutyric acid (GABA) and glutamate (Glu) and underlies T2 changes and deficient connectivity in functional networks in early recovery from NMDAR-antibody encephalitis. Our ambition is to identify the best potential prognostic biomarkers from these neurometabolite measurements and structural and functional MRI.
Our primary objective is to test the following specific hypotheses in children and young people with NMDAR-antibody encephalitis:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NMDAR-antibody encephalitis | Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis. |
| |
| Antibody-negative autoimmune encephalitis | Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis. |
| |
| Healthy control | Healthy children and young people (ages 8-24 years). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Not applicable - non-interventional study | Other | Not applicable - non-interventional study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cerebral concentrations of GABA and glutamate at the prefrontal cortex and left medial temporal lobe | Measured with MR spectroscopy - stimulated echo acquisition mode (STEAM) sequence | Baseline |
| Structural MRI | Quantitative MRI parameter maps including measurement of median T2 values in the hippocampus | Baseline |
| Resting-state fMRI | Whole-brain mapping of the default mode network and seed-based analysis of hippocampal-frontal connectivity | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Wechsler Abbreviated Scale of Intelligence 2nd Edition (WASI-II) | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Rey Auditory Verbal Learning Test (RAVLT) |
Not provided
INCLUSION CRITERIA:
NMDAR-antibody encephalitis group:
Antibody-negative autoimmune encephalitis group:
Healthy control group:
1. Age 8-24 years at study enrollment.
EXCLUSION CRITERIA:
All participants:
1. Any clear contra-indication for an MRI scan. In particular this would be due to the presence of any implanted devices or metal from previous surgery or accident.
Healthy control group:
1. A known neurological or neurodevelopmental disorder.
NMDAR-antibody encephalitis and antibody-negative autoimmune encephalitis groups:
Not provided
Not provided
All participants will be recruited in the United Kingdom.
NMDAR-antibody encephalitis and antibody-negative autoimmune encephalitis groups: Identified by neurologists/paediatric neurologists in secondary/tertiary healthcare settings, or by self-referral via the Encephalitis Society.
Healthy control group: Identified from King's College London volunteer databases, friends and siblings of autoimmune encephalitis cases, or recruited from local schools and colleges.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael R Eyre, MBBS MRes | Contact | +44 207 1887188 | 56322 | michael.eyre@kcl.ac.uk |
| David W Carmichael, PhD MSci | Contact | david.carmichael@kcl.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| David W Carmichael, PhD MSci | King's College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guy's and St Thomas' NHS Foundation Trust | Recruiting | London | Greater London | SE1 7EH | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26906964 | Background | Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20. |
Not provided
Not provided
Consent will be requested from participants to share imaging data and summary clinical and demographic data. Where participants consent, imaging data will be de-identified, removing facial features from the magnetic resonance images and all identifying information will be removed from the image header (the part of the file that describes how the image data was acquired). The resulting data will be shared together with anonymised clinical data at the request of other researchers.
Not provided
To be confirmed
Requests for data access from researchers at accredited research institutions will be considered. Any requests for data sharing may require a formal agreement to be put in place between the Sponsors and the recipient.
Not provided
Not provided
| ID | Term |
|---|---|
| D060426 | Anti-N-Methyl-D-Aspartate Receptor Encephalitis |
| D020274 | Autoimmune Diseases of the Nervous System |
| ID | Term |
|---|---|
| D020361 | Paraneoplastic Syndromes, Nervous System |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Cognitive test (higher score indicating better outcome)
| Baseline (all groups), 1 year (patients) |
| Doors & People Test | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Paired Associates Learning | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Rapid Visual Information Processing | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Spatial Span | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Intra-Extra Dimensional Set Shift | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Stockings of Cambridge | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| CANTAB (Cambridge Cognition, UK): Stop Signal Task | Cognitive test (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Prodromal Questionnaire Brief Version (PQ-B) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Patient Health Questionnaire (PHQ-9) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Generalized Anxiety Disorder 7-item Scale (GAD-7) | Questionnaire-based psychiatric symptom score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales | Questionnaire-based functional outcome score (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| PedsQL Multidimensional Fatigue Scale | Questionnaire-based functional outcome score (higher score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Behaviour Rating Inventory of Executive Function (BRIEF) | Questionnaire-based functional outcome score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| Conners 3 Short Form / Conners' Adult ADHD Rating Scale | Questionnaire-based functional outcome score (lower score indicating better outcome) | Baseline (all groups), 1 year (patients) |
| D010257 | Paraneoplastic Syndromes |
| D004660 | Encephalitis |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D019636 | Neurodegenerative Diseases |
| D000090862 | Neuroinflammatory Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |